Takahashi A, Kimura F, Yamanaka A, et al
Several factors have contributed to this: Influencers are claiming Retatrutide is the next breakthrough weight loss drug, often with no medical credentials or understanding of the undergoing clinical trials
According to the MHRA-approved SmPC, these include: Nausea represents the most frequently reported digestive side effect and is classified as very common (affecting more than 1 in 10 people)
The connection between autonomic neuropathy and conditions addressed by gut health peptides is increasingly recognized by researchers
The targeted, advanced action of the Zydus Semaglyn system offers efficient clinical management across multiple health indications
Li M, Xu S, Geng Y, Sun L, Wang R, Yan Y, et al